HomeAI · summaries
Storia in 5 fonti
FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each With Padcev® (enfortumab vedotin-ejfv), as Treatment Before and After Surgery for Adults With Muscle-Invasive Bladder Cancer (MIBC)
FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each With Padcev® (enfortumab vedotin-ejfv), as Treatment Before and After Surgery for Adults With Muscle-Invasive Bladder Cancer (MIBC)
Confronto fonti
5 prospettive sulla stessa storiaTimeline cronologica
- ·
healio.com
Pembrolizumab regimens snag FDA nod for muscle-invasive bladder cancer
The FDA has approved two immunotherapy combination therapies for adults with muscle-invasive bladder cancer. Pembrolizumab (Keytruda, Merck) or pembrolizumab and…
- ·
medpagetoday.com
FDA Expands Approval of Chemo-Free Bladder Cancer Combo in Curative Setting
Perioperative Keytruda-Padcev for MIBC approved regardless of cisplatin eligibility
